"The voice for cancer physicians and their patients in Massachusetts."

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 28 Jun 2019 11:10 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. Read full press release. 

  • 18 Jun 2019 12:01 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Read full press release. 

  • 11 Jun 2019 9:06 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Read full press release. 

  • 10 Jun 2019 2:06 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to polatuzumab vedotin-piiq (Polivy; Genentech), a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies. Read full press release.

  • 05 Jun 2019 11:51 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved the addition of overall survival data in labeling for gilteritinib (Xospata; Astellas) indicated for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. Read full press release. 

  • 28 May 2019 8:02 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved alpelisib (Piqray; Novartis) in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Read full press release. 

  • 16 May 2019 8:48 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved Herzuma (trastuzumab-pkrb; Celltrion) as a biosimilar to Herceptin (trastuzumab; Genentech) for patients with HER2-overexpressing breast cancer. Read full press release.

  • 16 May 2019 8:24 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Read full press release. 

  • 16 May 2019 8:14 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved venetoclax (Venclexta; AbbVie and Genentech) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read full press release. 

  • 13 May 2019 7:36 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ramucirumab (Cyramza; Lilly) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP of  ≥ 400 ng/mL and have been previously treated with sorafenib. Read full press release.

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

Upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software